Work

P01.01 HERTHENA-Lung01: A Randomized Phase 2 Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Previously Treated Metastatic EGFR-mutated NSCLC

Year: 2021

Type: conference-abstract

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2021.01.325

Authors: P. Janne, M. Johnson, Y. Goto, J.C. Yang, S. Karam, S. Chen, Y. Qiu, H. Yu, C. Yu

Institutions: Dana-Farber Cancer Institute, National Cancer Center Hospital, National Taiwan University Hospital, Daiichi Sankyo (United States), Memorial Sloan Kettering Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3136880682

Cites:

Cited by: 1

Related to: 10